1. Scrip
  2. >>Business

Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus

 
• By Alaric DeArment

The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.

Epilepsy awareness concept. Brain and encephalography in epilepsy patient during seizure attack, 3D illustration in purple color
Jazz laid out its Vision 2025 revenue target of $5bn at the J.P. Morgan conference last week • Source: Shutterstock

Jazz Pharmaceuticals plc’s goal of raking in $5bn in annual revenue within three years, up from an expected $3bn in 2021, stems in large part from a two-pronged focus on neurology and oncology, with the bulk of growth coming from its existing products.

CEO Bruce Cozadd reaffirmed the firm’s 2021 revenue guidance of more than $3bn and laid out Jazz’s “Vision 2025” plan on 10 January at the J.P. Morgan Healthcare Conference. The strategy will rely heavily on the company’s oxybate franchise – including Xywav (calcium oxybate/magnesium oxybate/sodium oxybate) for narcolepsy and idiopathic hypersomnia (IH) and branded and authorized-generic versions of Xyrem (sodium oxybate) narcolepsy – generating $2bn. Another $2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

More from Scrip

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.